Alert detail
LCD L39270: Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin — Palmetto GBA
What changed
Palmetto GBA finalizes allo-HCT coverage for relapsed/refractory lymphoma.
Who’s affected: Oncology billing teams · Effective: December 19, 2024
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
This change affects 10 billing codes.
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.